

John B Kostis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2555140/publications.pdf>

Version: 2024-02-01

64
papers

3,545
citations

361045

20
h-index

149479

56
g-index

65
all docs

65
docs citations

65
times ranked

4507
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA - Journal of the American Medical Association, 2016, 315, 2673.	3.8	991
2	Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004, 17, 103-111.	1.0	492
3	The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings, 2012, 87, 766-778.	1.4	403
4	Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. American Journal of Cardiology, 2005, 95, 29-35.	0.7	320
5	Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms. Frontiers in Oncology, 2015, 5, 39.	1.3	232
6	Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). American Journal of Cardiology, 2005, 96, 85-93.	0.7	112
7	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. American Heart Journal, 2002, 144, 636-641.	1.2	101
8	Effect of anemia on 1-year mortality in patients with acute myocardial infarction. American Heart Journal, 2002, 144, 636-641.	1.2	88
9	All Men with Vasculogenic Erectile Dysfunction Require a Cardiovascular Workup. American Journal of Medicine, 2014, 127, 174-182.	0.6	74
10	Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia. Journal of Clinical Pharmacology, 1994, 34, 989-996.	1.0	70
11	Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival. JAMA - Journal of the American Medical Association, 2011, 306, 2588.	3.8	68
12	The Effect of Statins on Erectile Dysfunction: A Meta-Analysis of Randomized Trials. Journal of Sexual Medicine, 2014, 11, 1626-1635.	0.3	55
13	The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2007, 21, 297-309.	1.3	49
14	Percutaneous transluminal coronary angioplasty in situs inversus. Catheterization and Cardiovascular Diagnosis, 1987, 13, 114-116.	0.7	39
15	Risk Factors and Trends in Incidence of Heart Failure Following Acute Myocardial Infarction. American Journal of Cardiology, 2018, 122, 1-5.	0.7	31
16	Visit-to-Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program. Journal of Clinical Hypertension, 2014, 16, 34-40.	1.0	29
17	Limitations of Randomized Clinical Trials. American Journal of Cardiology, 2020, 129, 109-115.	0.7	29
18	Erectile Dysfunction Is Common among Patients with Gout. Journal of Rheumatology, 2015, 42, 1893-1897.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Pharmacologic Therapy for Erectile Dysfunction and its Interaction With the Cardiovascular System. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 53-64.	1.0	22
20	Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2011, 5, 97-104.	0.6	20
21	Fosinopril: Pharmacokinetics and pharmacodynamics in congestive heart failure*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 660-665.	2.3	19
22	The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. <i>American Journal of Hypertension</i> , 1998, 11, 1433-1441.	1.0	18
23	From hypertension to heart failure: update on the management of systolic and diastolic dysfunction. <i>American Journal of Hypertension</i> , 2003, 16, 18-22.	1.0	18
24	Uses and opportunities for machine learning in hypertension research. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100027.	2.2	15
25	Statins and Cataracts—a Visual Insight. <i>Current Atherosclerosis Reports</i> , 2015, 17, 477.	2.0	14
26	Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial Infarction. <i>Clinical Pharmacokinetics</i> , 2002, 41, 445-452.	1.6	13
27	The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. <i>Journal of Clinical Hypertension</i> , 2008, 10, 367-376.	1.0	13
28	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure. <i>Hypertension</i> , 2021, 77, 813-822.	1.3	13
29	Effect of cholesterol lowering with statins orÂ proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 728-733.	0.6	12
30	Statins and Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2019, 37, 1.	1.7	12
31	The effect of treatment on survival in congestive heart failure. <i>Clinical Cardiology</i> , 1992, 15, 323-329.	0.7	11
32	Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 319-327.	0.7	11
33	Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years. <i>American Journal of Cardiology</i> , 2020, 125, 1154-1157.	0.7	11
34	A New Approach to Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2007, 120, 746-747.	0.6	9
35	Antihypertensive Therapy With CCB/ARB Combination in Older Individuals: Focus on Amlodipine/Valsartan Combination. <i>American Journal of Therapeutics</i> , 2010, 17, 188-196.	0.5	9
36	Competing Cardiovascular and Noncardiovascular Risks and Longevity in the Systolic Hypertension in the Elderly Program. <i>American Journal of Cardiology</i> , 2014, 113, 676-681.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Disputation on the Use of Age in Determining the Need for Treatment of Hypercholesterolemia and Hypertension. <i>Journal of Clinical Hypertension</i> , 2006, 8, 519-520.	1.0	8
38	International medical graduates and the cardiology workforce. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1172-1174.	1.2	7
39	Hypertension: Definitions and Guidelines. <i>Journal of Clinical Hypertension</i> , 2005, 7, 538-539.	1.0	7
40	Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial. <i>Journal of Sexual Medicine</i> , 2020, 17, 238-248.	0.3	7
41	Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss. <i>American Heart Journal</i> , 2002, 144, 625-629.	1.2	6
42	Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 387-389.	2.3	6
43	Blood pressure is a beautiful (but imperfect) biomarker of hypertension. The quixotic quest that fuels the hypertension guideline industry. <i>Journal of Clinical Hypertension</i> , 2018, 20, 840-841.	1.0	5
44	Relation Between Statewide Hospital Performance Reports on Myocardial Infarction and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2019, 123, 1587-1594.	0.7	5
45	Readmission and mortality among heart failure patients with history of hypertension in a statewide database. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1263-1274.	1.0	5
46	Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. <i>Journal of Clinical Hypertension</i> , 2022, , .	1.0	5
47	Angiotensin Converting Enzyme Inhibitors in Hypertension. <i>Cardiovascular Drug Reviews</i> , 1989, 7, 173-176.	4.4	4
48	Statin Use and Cataract. <i>JAMA Ophthalmology</i> , 2014, 132, 363.	1.4	4
49	Response to Letter on "Statin Use and Risk of Cataracts. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 346-347.	1.0	4
50	The Legacy Effect in Treating Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 291-298.	1.0	4
51	Differences Among ACE Inhibitors. <i>American Journal of Hypertension</i> , 2010, 23, 1156-1156.	1.0	2
52	Quality of Meta-Analyses for Randomized Trials in the Field of Hypertension: an Updated and Improved Systematic Review. <i>Current Hypertension Reports</i> , 2017, 19, 71.	1.5	2
53	Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT). <i>Journal of Clinical Hypertension</i> , 2021, 23, 1335-1343.	1.0	2
54	Relation of Socioeconomic Status to 1-Year Readmission and Mortality in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2022, 175, 19-25.	0.7	2

#	ARTICLE	IF	CITATIONS
55	HOPE-3 and SPRINT: two landmark trials with different outcomes?. Journal of the American Society of Hypertension, 2016, 10, 477-481.	2.3	1
56	Prediction of stroke using an algorithm to estimate arterial stiffness. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 11, 200114.	0.4	1
57	Hemostatic Function and Coronary Artery Disease. Circulation, 2000, 101, E195.	1.6	0
58	Response to Letter by Bath et al. Stroke, 2008, 39, .	1.0	0
59	Statin Use and Risk of Cataract Response to Letter. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 223-223.	1.0	0
60	Visit-to-visit variability of blood pressure. Journal of the American Society of Hypertension, 2017, 11, 473-474.	2.3	0
61	Blood pressure levels for patients with acute coronary syndromes. Journal of Clinical Hypertension, 2019, 21, 1144-1144.	1.0	0
62	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 397-397.	1.0	0
63	Use of advanced statistical techniques to predict all-cause mortality in the Systolic Blood Pressure Intervention Trial. International Journal of Cardiology: Hypertension, 2020, 7, 100053.	2.2	0
64	Critical Question in Cardiovascular Risk: Can we use clinical trials to improve the outcomes of patients with hypertension?. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 11, 200108.	0.4	0